Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink Jul 9, 2015
Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association’s (ADA) Scientific Sessions in Boston, MA Jun 9, 2015
Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement Apr 28, 2015